bradykinin receptors on adventitial fibroblasts of cerebral arteries are coupled to recombinant eNOS. Am. J. Physiol. Heart Circ. Physiol. 278: H367-H372, 2000.-Our previous ex vivo and in vivo studies reported that expression of the recombinant endothelial nitric oxide (NO) synthase (eNOS) gene in adventitial fibroblasts recovers NO production in arteries without endothelium in response to bradykinin. The present study was designed to characterize subtypes of bradykinin receptors on adventitial fibroblasts coupled to the activation of recombinant eNOS. Endothelium-denuded segments of canine basilar arteries were transduced with ␤-galactosidase (␤-Gal) gene or eNOS gene ex vivo, using a replication-defective adenoviral vector (10 10 plaque-forming units/ml) for 30 min at 37°C. Twenty-four hours later, isometric force recording or cGMP measurement was carried out. B 1 bradykinin receptor agonist (des-Arg 9 -bradykinin, 10 Ϫ10 -10 Ϫ8 mol/l) did not significantly affect vascular tone in control or ␤-Gal gene-transduced canine basilar arteries without endothelium. In contrast, this agonist caused concentrationdependent relaxations in recombinant eNOS gene-transduced arteries without endothelium. Relaxations to B 1 receptor agonist in the eNOS arteries were abolished by B 1 receptor antagonist (des-Arg 9 -[Leu 8 ]bradykinin, 6 ϫ 10 Ϫ9 mol/l) but not by B 2 receptor antagonist (Hoe-140, 5 ϫ 10 Ϫ8 mol/l). Bradykinin did not significantly alter vascular tone in control or ␤-gal arteries without endothelium, whereas this peptide (10 Ϫ11 -10 Ϫ8 mol/l) induced concentration-dependent relaxations, as well as an increase in cGMP formation in endothelium-denuded eNOS-transduced arteries. Stimulatory effects of bradykinin were prevented in the presence of a B 2 receptor antagonist but not in the presence of a B 1 receptor antagonist. B 1 and B 2 receptor antagonists had no effect on relaxations to substance P, confirming the selectivity of the compounds. Our results suggest that B 1 and B 2 bradykinin receptors are coupled to activation of recombinant eNOS expressed in adventitial fibroblasts.
deduced amino acid sequences indicate that both receptors belong to the G protein-coupled superfamily of receptors with seven transmembrane domains. The B 1 receptor has a higher affinity for the bradykinin metabolite des-Arg 9 -bradykinin than it does for bradykinin itself and can be blocked by the selective antagonist des-Arg 9 -[Leu 8 ]bradykinin. The B 2 receptor has a higher affinity for bradykinin than it does for des-Arg 9 -bradykinin and is blocked by the potent and selective B 2 receptor antagonist Hoe-140.
Nitric oxide (NO) possesses a powerful vasodilator effect (4, 13, 19, 20) , and it inhibits vascular smooth muscle cell proliferation (11) , platelet aggregation (21) , and leukocyte adhesion (14) . All of these effects might be beneficial in the prevention and/or treatment of cardiovascular disorders. Gene transfer of recombinant endothelial NO synthase (eNOS) offers potential for altering vessel wall physiology and intervening in diseased blood vessels. We previously reported successful transfer and functional expression of recombinant eNOS gene in the adventitia of canine cerebral arteries ex vivo (7, 23, 25) and in vivo (6) . Interestingly, perivascular eNOS gene delivery restored NO production in arteries without endothelium and induced the endothelium-independent, adventitia-dependent relaxations in response to bradykinin. Immunogold labeling and electron microscopy indicated that recombinant eNOS protein was predominantly expressed in adventitial fibroblasts, supporting a novel concept that fibroblasts in the adventitia may play a role in the regulation of vascular tone after successful transfer and expression of recombinant eNOS gene. The present study was designed to characterize subtypes of bradykinin receptors on adventitial fibroblasts coupled to activation of recombinant eNOS.
MATERIALS AND METHODS

Adenoviral vectors.
The adenoviral vector encoding an eNOS gene driven by the cytomegalovirus immediate early promoter was generated through homologous recombination. These vectors, based on serotype 5 wild adenovirus, have been made replication deficient by a deletion of the early region 1, which was replaced by a cDNA sequence encoding bovine aortic endothelial cell eNOS (kindly provided by Dr. David G. Harrison, Emory University, Atlanta, GA). The generation, propagation, purification, and evaluation of the adenoviral vector containing eNOS gene were described in detail previously (7) . The recombinant adenoviral vector encoding ␤-galactosidase (␤-Gal) gene driven by cytomegalo-
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virus promoter, used in all experiments as a control, was a kind gift of Dr. James M. Wilson (University of Pennsylvania, Philadelphia, PA).
Gene transfer. All procedures were in accordance with Institutional Animal Care and Use Committee guidelines of Mayo Clinic. Rings (3 mm long) of basilar artery were taken from mongrel dogs (18-27 kg) intravenously anesthetized with 30 mg/kg pentobarbital sodium. Arterial rings were gently rinsed with Krebs-Ringer bicarbonate solution (in mmol/l: 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25.0 NaHCO 3 , 0.0026 calcium EDTA, and 11.1 glucose) to remove blood. In all rings of basilar arteries, endothelium was removed mechanically. The surface of the needles (19-22 gauge) was made rough with sandpaper, and the needles were fixed for denudation in a dish filled with Krebs-Ringer bicarbonate solution. Endothelial removal was accomplished by sliding an arterial segment over the needle with two pairs of fine forceps under a microscope (6, 23, 25) . After this procedure, the rings were randomly assigned for gene transfer. Arterial rings were transduced with an adenoviral vector in minimum essential medium (MEM) (with Earle's salts, containing 0.1% BSA, 100 U/ml penicillin, and 100 µg/ml streptomycin) for 30 min at 37°C and then transferred to fresh MEM and incubated for 24 h at 37°C in a CO 2 incubator (5% CO 2 -95% air) (Forma Scientific, Marietta, OH) (6, 23, 25) . Control arteries (nontransduced arteries) were incubated in MEM for 24 h in the same manner.
Vascular reactivity. Twenty-four hours after gene transfer, arterial rings were connected to isometric force-displacement transducers (Grass Instruments, Quincy, MA) and suspended in organ chambers filled with 25 ml of Krebs-Ringer bicarbonate solution (pH 7.4, 37°C) gassed with 94% O 2 -6% CO 2 . Isometric force was recorded continuously. Arteries were allowed to stabilize for 1 h. The rings were then stretched progressively to optimal force (ϳ3 g), determined by repeated stimulation with 10 Ϫ5 mol/l UTP (1). Concentration-response curves to des-Arg 9 -bradykinin (10 Ϫ10 -10 Ϫ8 mol/l), bradykinin (10 Ϫ11 -3 ϫ 10 Ϫ9 mol/l) or substance P (10 Ϫ11 -3 ϫ 10 Ϫ9 mol/l) were cumulatively obtained during submaximal contractions with median effective concentration (EC 50 ) of UTP (3 ϫ 10 Ϫ6 -5 ϫ 10 Ϫ5 mol/l). To inhibit cyclooxygenase activity, all experiments were performed in the presence of indomethacin (10 Ϫ5 mol/l). The incubation time with indomethacin or N G -nitro-L-arginine methyl ester (L-NAME) was 30 or 15 min, respectively. The incubation times with B 1 antagonist desArg 9 -[Leu 8 ]bradykinin and B 2 antagonist Hoe-140 were both 25 min. The relaxations were expressed as a percentage of maximal relaxations induced by papaverine (3 ϫ 10 Ϫ4 mol/l). In all experiments, arterial rings taken from the same dogs were studied in parallel. Intracellular cGMP levels. A radioimmunoassay technique was used to determine the levels of cGMP, as reported previously (23, 24) . Twenty-four hours after gene transfer, 10 Ϫ5 mol/l indomethacin and 10 Ϫ3 mol/l 3-isobutyl-1-methylxanthine were added to the incubation medium for 30 min at 37°C to inhibit cyclooxygenase activity and the degradation of cGMP by phosphodiesterases, respectively. Arteries were incubated in the presence of B 1 antagonist des-Arg 9 -[Leu 8 ]bradykinin or B 2 antagonist Hoe-140 for 25 min, respectively. During the last 2 min of the 30-min incubation period, certain rings were stimulated with 10 Ϫ9 mol/l bradykinin. Rings were then removed from the medium and quickly frozen in liquid nitrogen. After homogenization, cGMP levels were measured by a cGMP RIA kit (Amersham, Arlington Heights, IL). Total protein levels were determined by the Lowry et al. (15) method. Arterial rings taken from the same dogs were studied in parallel.
Drugs. The following agents were used: bradykinin, desArg 9 -[Leu 8 ]bradykinin, substance P, indomethacin, UTP, papaverine hydrochloride, L-NAME, 3-isobutyl-1-methylxanthine (Sigma Chemical, St. Louis, MO), des-Arg 9 -bradykinin, Hoe-140 (Phoenix Pharmaceuticals, Mountain View, CA), fetal bovine serum, MEM, and penicillin-streptomycin (GIBCO BRL, Grand Island, NY). Indomethacin was dissolved with equal molar concentrations of Na 2 CO 3 . All concentrations are expressed as final molar concentration in medium or solution.
Statistical analysis. The results are expressed as means Ϯ SE. In each set of experiments, n refers to the number of animals studied. Statistical evaluation of the data was performed by ANOVA, followed by Bonferroni-Dunn's post hoc test (16) . A value of P Ͻ 0.05 was considered to be statistically significant.
RESULTS
Effect of B 1 bradykinin receptor agonist. B 1 receptor agonist des-Arg 9 -bradykinin did not significantly affect vascular tone in control or ␤-Gal gene-transduced canine basilar arteries without endothelium (Fig. 1A) . In contrast, in recombinant eNOS gene-transduced arteries without endothelium, des-Arg 9 -bradykinin (10 Ϫ10 -10 Ϫ8 M) caused concentration-dependent relaxations (P Ͻ 0.05) (Fig. 1A) . The presence of endothelium did not affect the relaxations to des-Arg 9 -bradykinin in the eNOS arteries ( Table 1 ). The relaxant effect of des-Arg 9 -bradykinin was abolished by a NOS inhibitor L-NAME (3 ϫ 10 Ϫ4 mol/l) (P Ͻ 0.05) ( Table 2) . Relaxations to des-Arg 9 -bradykinin in the eNOS arteries were antagonized by B 1 receptor antagonist des-Arg 9 -[Leu 8 ]bradykinin (6 ϫ 10 Ϫ9 mol/l) (P Ͻ 0.05) but not by B 2 receptor antagonist Hoe-140 (5 ϫ 10 Ϫ8 mol/l) (Fig.  1B) . B 1 receptor antagonist had little effect on relaxations to substance P in control ( Fig. 2A) and eNOS gene-transduced arteries with endothelium (data not shown), confirming the selectivity of the compound. Table 2 Data are means Ϯ SE, expressed as percentage of maximal relaxation induced by papaverine (3 ϫ 10 Ϫ4 mol/l; 100% ϭ 4.6 Ϯ 0.3 g and 4.7 Ϯ 0.6 g) for rings without and with L-NAME, respectively; n ϭ 6 dogs. A nitric oxide synthase (NOS) inhibitor N G -nitro-L-arginine methyl ester (L-NAME, 3 ϫ 10 Ϫ4 mol/l) abolished relaxant effect of des-Arg 9 -bradykinin in eNOS rings without endothelium (P Ͻ 0.05). Statistical evaluation was performed by two-way repeated measure ANOVA. 
. Effect of a NOS inhibitor L-NAME on relaxations to des-Arg 9 -bradykinin in canine basilar artery rings without endothelium transduced with recombinant eNOS gene
Effect of bradykinin.
Bradykinin did not significantly alter vascular tone in control or ␤-Gal arteries without endothelium, whereas this peptide (10 Ϫ11 -10 Ϫ8 mol/l) induced concentration-dependent relaxations in eNOS arteries without endothelium (P Ͻ 0.05) (Fig. 3A) . The stimulatory effect of bradykinin was prevented in the presence of B 2 receptor antagonist Hoe-140 (5 ϫ 10 Ϫ8 mol/l) (P Ͻ 0.05) but not in the presence of B 1 receptor antagonist des-Arg 9 -[Leu 8 ]bradykinin (6 ϫ 10 Ϫ9 mol/l) (Fig. 3B) . The selectivity of B 2 receptor antagonist was confirmed by the fact that it did not affect relaxations to substance P in control (Fig. 2B) and eNOS gene-transduced (data not shown) arteries with endothelium.
Cellular cGMP levels. Bradykinin significantly enhanced intracellular cGMP formation in eNOS arteries without endothelium (P Ͻ 0.05), which was prevented by pretreatment with B 2 receptor antagonist Hoe-140 (5 ϫ 10 Ϫ8 mol/l) (P Ͻ 0.05) but not with B 1 receptor antagonist des-Arg 9 -[Leu 8 ]bradykinin (6 ϫ 10 Ϫ9 mol/l) (Fig. 4) . Those antagonists did not change basal cGMP levels (Fig. 4) .
DISCUSSION
Our previous ex vivo (23) and in vivo (6) studies demonstrated that genetically engineered adventitial fibroblasts transduced with recombinant eNOS gene restore production of NO in arteries without endothelium in response to bradykinin. The major new findings of the present study are that B 1 and B 2 bradykinin receptors on adventitial fibroblasts are coupled to activation of recombinant eNOS and that stimulatory effect of bradykinin on NO formation appears to be mediated by activation of B 2 receptors.
It is well established that competitive B 1 receptor antagonist des-Arg 9 -[Leu 8 ]bradykinin and noncompetitive B 2 receptor antagonist Hoe-140 are highly selective (3, 22) . In the present study, pretreatment with des-Arg 9 -[Leu 8 ]bradykinin virtually prevented B 1 agonist-elicited relaxations in eNOS arteries, whereas that with Hoe-140 was without effect. Moreover, des-Arg 9 -[Leu 8 ]bradykinin and Hoe-140 did not affect other receptor-mediated relaxations (substance P-evoked relaxations), confirming the selectivity of these compounds under the present experimental conditions. We have recently demonstrated the adventitial fibroblast-dependent relaxations of canine basilar arteries transduced with recombinant eNOS gene (25) . Serum, substance P, angiotensin II, and bradykinin, all of which are known to increase intracellular calcium concentrations in fibroblasts, evoke significant concentration-dependent relaxations in eNOS arteries without endothelium. More importantly, chemical (ethanol treatment) or mechanical (adventitial rubbing) disruption of adventitial cell function significantly attenuated relaxations induced by those substances in the endothelium-denuded eNOS arteries (25) . In the present study, B 1 agonist-stimulated relaxations in eNOS arteries were almost identical in the presence and the absence of endothelial cells, further supporting our conclusion that observed relaxations in eNOS arteries are dependent on activation of adventitial fibroblasts. B 2 bradykinin receptor is constitutively expressed in different cell types and tissues (3, 22) . Although constitutive expression of B 1 bradykinin receptor has been shown in the dog coronary system and in the cat pulmonary vascular bed, B 1 receptor is in general thought to be induced under certain pathological conditions such as tissue injury or inflammation (3, 22) . Adenoviral-mediated gene transfer itself appears not to induce B 1 receptor in endothelial cells, because in arteries with endothelium transduction with ␤-Gal gene did not cause endothelium-dependent relaxations in response to stimulation of B 1 receptor (M. Tsutui and Z. S. Katusic, unpublished observations). It remains to be elucidated whether or not adenoviral-mediated transduction of the recombinant eNOS gene might induce B 1 receptor in fibroblasts of basilar artery adventitia.
Bradykinin is formed within the arterial wall from kininogen by kallikreins (3, 22) . High activity of angiotensin-converting enzyme, which not only transforms angiotensin I into angiotensin II but also converts bioactive bradykinin to inactive peptide (26) , has been detected in human vascular adventitia (27) . Further studies are certainly needed to determine whether under physiological or pathological conditions the locally released bradykinin can indeed activate recombinant eNOS protein expressed in adventitial fibroblasts following in vivo eNOS gene transfer. B 1 and B 2 bradykinin receptors exist in fibroblasts, as indicated by the fact that cloning of both receptors was carried out by using a fibroblast cell line (12, 17) . Activation of bradykinin receptors on fibroblasts leads to elevation of cellular calcium concentrations through extracellular calcium influx and intracellular calcium release (2, 5) . After ex vivo and in vivo eNOS gene transfer into cerebral arteries, electron microscopy immunogold labeling demonstrated that recombinant eNOS enzyme is localized in caveolae of adventitial fibroblasts (9, 10, 18) . Stimulation with bradykinin has been shown to recruit and sequester B 2 bradykinin receptors, and the receptor-coupled G protein ␣-subunits G␣ -q and G␣ -i in caveolae (8) and activation of bradykinin receptors in caveolae might promote eNOS depalmitoylation, which could lead to the release and translocation of eNOS from caveolae to the cytosol (18) .
Thus the adventitial fibroblasts may be well equipped with machinery for bradykinin receptor-mediated, caveolae-associated activation of recombinant eNOS enzyme.
In summary, the present study has demonstrated the coupling of B 1 and B 2 bradykinin receptors with NO formation in fibroblasts expressing recombinant eNOS enzymatic activity. Adventitial fibroblasts may be optimal target cells for delivery of recombinant eNOS in protocols designed to restore or increase NO production in cerebral arteries.
